Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Company Overview

Gemini Therapeutics is a clinical-stage biotechnology company focused on developing novel complement pathway therapeutics for neurodegenerative diseases. The company’s research platform leverages computational protein design and engineering to create optimized complement regulators capable of crossing the blood–brain barrier. By targeting key nodes in the complement cascade, Gemini aims to modulate innate immune activity in the central nervous system and potentially slow or halt disease progression.

Headquartered in Cambridge, Massachusetts, Gemini Therapeutics was founded in 2016 and maintains both discovery and translational research operations in the Greater Boston area. Its lead program is designed to restore balance in complement activity through engineered versions of complement factor H, with a pipeline that also includes additional candidates for Alzheimer’s disease and other age-related neurodegenerative disorders. Preclinical studies have demonstrated promising target engagement and safety profiles, supporting anticipated progression into early-stage clinical trials.

The company’s leadership team comprises experienced executives and scientists drawn from immunology, protein engineering and neuroscience disciplines. Gemini Therapeutics collaborates with academic institutions and industry partners to advance its programs, aiming to address significant unmet medical needs in neurodegeneration through precision modulation of the innate immune system.

Key Stats

• Today's Range: $57.43 to $62.00
• 50-Day Range: $44.24 to $58.00
• 52-Week Range: $1.16 to $14.10
• Volume: 672,319 shs
• Average Volume: 189,291 shs
• Market Capitalization: $2.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GMTX Stock Analysis - Frequently Asked Questions

How have GMTX shares performed this year?

Gemini Therapeutics' stock was trading at $63.40 at the start of the year. Since then, GMTX shares have decreased by 8.9% and is now trading at $57.77.

How were Gemini Therapeutics' earnings last quarter?

Gemini Therapeutics, Inc. (NASDAQ:GMTX) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04.

How do I buy shares of Gemini Therapeutics?

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gemini Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and Shopify (SHOP).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 7/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GMTX
• CIK: 1816736
• Web: www.geminitherapeutics.com
• Phone: 415-877-4887
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.78%
• Return on Assets: -35.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 71.49
• Quick Ratio: 71.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: 19.99

Miscellaneous

• Outstanding Shares: 43,328,000
• Free Float: 37,739,000
• Market Cap: $2.50 billion
• Optionable: Not Optionable
• Beta: -0.12